Literature DB >> 12772497

Recent advances in immunostimulatory CpG oligonucleotides.

Simon Rothenfusser1, Evelyn Tuma, Moritz Wagner, Stefan Endres, Gunther Hartmann.   

Abstract

The vertebrate immune system has evolved a mechanism to detect CpG motifs within microbial DNA (CpG DNA). Synthetic oligonucleotides containing CpG motifs (CpG ODNs) are potent immunomodulatory molecules and outstanding vaccine adjuvants. A number of recent findings have greatly improved our understanding of the biology of CpG DNA, and the immunological effects of CpG DNA are now recognized to be distinct in mouse and human. The plasmacytoid dendritic cell (PDC) was identified to play a pivotal role in mediating CpG-induced immune responses. So far, the B-cell is the only other immune cell subset in humans besides the PDC, equipped with the toll-like receptor-9 to detect CpG motifs. The information on these two prime CpG-sensitive cells has allowed the identification of novel CpG ODNs with distinct functional activity. Together with exciting contributions from animal studies, the way seems to be paved for the successful clinical development of this novel class of molecular therapeutics.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12772497

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN: 1464-8431


  10 in total

Review 1.  Hypothesis driven development of new adjuvants: short peptides as immunomodulators.

Authors:  Jessica C Dong; Gary P Kobinger
Journal:  Hum Vaccin Immunother       Date:  2013-04-01       Impact factor: 3.452

2.  Induction of liver-specific intrahepatic myeloid cells aggregation expands CD8 T cell and inhibits growth of murine hepatoma.

Authors:  Yung-Chang Lin; Chen-Yu Hsu; Sheng-Kai Huang; Yun-Han Fan; Chien-Hao Huang; Chan-Keng Yang; Wan-Ting Su; Po-Chia Chang; Avijit Dutta; Yu-Jen Liu; Ching-Tai Huang; Tse-Ching Chen; Chun-Yen Lin
Journal:  Oncoimmunology       Date:  2018-09-19       Impact factor: 8.110

Review 3.  Non-human primate models for AIDS vaccine research.

Authors:  Shiu-Lok Hu
Journal:  Curr Drug Targets Infect Disord       Date:  2005-06

4.  Structure-dependent modulation of alpha interferon production by porcine circovirus 2 oligodeoxyribonucleotide and CpG DNAs in porcine peripheral blood mononuclear cells.

Authors:  Frida Hasslung Wikström; Brian M Meehan; Mikael Berg; Sirje Timmusk; Josefine Elving; Lisbeth Fuxler; Mattias Magnusson; Gordon M Allan; Francis McNeilly; Caroline Fossum
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

5.  Deoxycytidyl-deoxyguanosine oligonucleotide classes A, B, and C induce distinct cytokine gene expression patterns in rhesus monkey peripheral blood mononuclear cells and distinct alpha interferon responses in TLR9-expressing rhesus monkey plasmacytoid dendritic cells.

Authors:  Kristina Abel; Yichuan Wang; Linda Fritts; Eleonora Sanchez; Eugene Chung; Patricia Fitzgerald-Bocarsly; Arthur M Krieg; Christopher J Miller
Journal:  Clin Diagn Lab Immunol       Date:  2005-05

6.  Enhanced antibody responses to a detoxified lipopolysaccharide-group B meningococcal outer membrane protein vaccine are due to synergistic engagement of Toll-like receptors.

Authors:  Wilbur H Chen; Subhendu Basu; Apurba K Bhattacharjee; Alan S Cross
Journal:  Innate Immun       Date:  2009-10-12       Impact factor: 2.680

7.  Immunological properties of gold nanoparticles.

Authors:  Lev A Dykman; Nikolai G Khlebtsov
Journal:  Chem Sci       Date:  2016-11-16       Impact factor: 9.825

Review 8.  Progress towards in vivo use of siRNAs.

Authors:  Mark A Behlke
Journal:  Mol Ther       Date:  2006-02-14       Impact factor: 11.454

Review 9.  Gold nanoparticles for preparation of antibodies and vaccines against infectious diseases.

Authors:  Lev A Dykman
Journal:  Expert Rev Vaccines       Date:  2020-04-28       Impact factor: 5.217

Review 10.  Activation of Innate Immunity by Therapeutic Nucleic Acids.

Authors:  Ali Bishani; Elena L Chernolovskaya
Journal:  Int J Mol Sci       Date:  2021-12-12       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.